Several of these studies are phase 2 studies for second line treatment of advanced tumors designed with an anti-angiogenic agent, targeting VEGFR or VEGF, and with chemotherapy directed towards tumor cells (e.g., NCT01744249, NCT02704767 or NCT03503604). This evidence concerns the gene VEGFA and neoplasm.